# A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

> **NCT00866047** · PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 58 (actual)

## Conditions studied

- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** brentuximab vedotin

## Key facts

- **NCT ID:** NCT00866047
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-08
- **Final completion:** 2016-06
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2017-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866047, "A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00866047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*